Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
SpyGlass Pharma
Aliso Viejo, California, United Statesspyglasspharma.com ↗
- Ownership
- Public · SGP
- Development stage
- Other
01
Overview
The company completed enrollment in Phase I/II trials in November 2024. 18-month data showed 100% of patients remained off all topical IOP-lowering drops, all patients achieved an IOP reduction of more than 20% from baseline, and 96% of patients maintained an IOP ≤18 mmHg. The platform was well-tolerated with no product-related adverse events.[4][5]
- Therapeutic areas
- Ophthalmology
- Modalities
- Drug delivery platformControlled release drug delivery
- Industry
- Implantable Medical Devices
02
Financials
- Market cap
- $1.1B
- Total revenue
- $0
- Enterprise value
- $907.4M
Beyond the preview
Go deeper on SpyGlass Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SpyGlass Pharma.